Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Blood (2025) 146 (Supplement 1): 396.

https://doi.org/10.1182/blood-2025-396

Published: 2025

Journal Articles

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Blood (2025) 146 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2025-4350

Published: 2025

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure

Brian Ball, MD, Rami S. Komrokji, MD, Lionel Ades, MD PhD, Mikkael A. Sekeres, MD MS, Amy E. DeZern, MD MHS, Lisa Pleyer, MD DI, Norbert Vey, MD PhD, Antonio Almeida, MD PhD, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, MD, Steven Gore, Pierre Fenaux, MD PhD, Thomas Prebet, MD PhD

Blood (2016) 128 (22): 348.

https://doi.org/10.1182/blood.V128.22.348.348

Published: 2016

Journal Articles

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

Guillermo Garcia-Manero, MD, Valeria Santini, MD, Antonio Almeida, MD PhD, Pierre Fenaux, MD PhD, Norbert Gatterman, MD PhD, Keiya Ozawa, MD PhD, Stuart L. Goldberg, MD, Jerry Weaver, PhD, Mary M. Sugrue, MD PhD

Blood (2016) 128 (22): 3190.

https://doi.org/10.1182/blood.V128.22.3190.3190

Published: 2016

Journal Articles

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas CP Cross, MA, PhD, Andrzej Hellmann, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Almeida, MD PhD, Arpad Illes, MD PhD, Miguel Sagues, MD, Jens Haenig, PhD, Sharon Supekar, MSc, Seema Shah, MSc, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, Michele Baccarani, MD

Blood (2016) 128 (22): 3094.

https://doi.org/10.1182/blood.V128.22.3094.3094

Published: 2016

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2016) 128 (22): 3186.

https://doi.org/10.1182/blood.V128.22.3186.3186

Published: 2016

Journal Articles

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Antonio Almeida, MD PhD, Valeria Santini, MD, Stefanie Gröpper, MD, Anna Jonasova, MD, Norbert Vey, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Guillermo Sanz, MD PhD, Barry Skikne, MD, Albert Hoenekopp, MD, Francis Séguy, Jianhua Zhong, PhD, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2880.

https://doi.org/10.1182/blood.V126.23.2880.2880

Published: 2015

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

Vorinostat Impairs Cellular Viability, Differentiation, Redox Homeostasis and Gene Expression in BCR-ABL-Negative Myeloproliferative Neoplasms

Bruno A Cardoso, PhD, Helio Belo, MSc, Antonio Almeida, MD PhD

Blood (2014) 124 (21): 3222.

https://doi.org/10.1182/blood.V124.21.3222.3222

Published: 2014

Journal Articles

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Blood (2014) 124 (21): 151.

https://doi.org/10.1182/blood.V124.21.151.151

Published: 2014

Journal Articles

Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis

Bruno A Cardoso, PhD, Helio Belo, MSc, Ana Isabel Oliveira, MSc, Olga Pereira, MSc, Joao T Barata, PhD, Antonio Almeida, MD PhD

Blood (2014) 124 (21): 910.

https://doi.org/10.1182/blood.V124.21.910.910

Published: 2014

Journal Articles

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Blood (2014) 124 (21): 409.

https://doi.org/10.1182/blood.V124.21.409.409

Published: 2014

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

Epigenetic Alterations In Fanconi Anemia: Role In Disease Progression and Therapeutic Potential

Helio Belo, Gabriela Medeiros Silva, PhD, Bruno Cardoso, PhD, Beatriz Porto, PhD, José Barbot, M.D, Jorge Coutinho, M.D, Juan A Bueren, PhD, Jordi Surralles, PhD, Jose A Casado, PhD, Manuela Benedito, M.D, Hema Saturnino, M.D, Emília Costa, M.D, Maria Gomes Silva, MD, PhD, Antonio Almeida, MD, PhD

Blood (2013) 122 (21): 4865.

https://doi.org/10.1182/blood.V122.21.4865.4865

Published: 2013

Journal Articles

Azacitidine for the Treatment of Acute Erythroleukemia: Three Case Reports

Francesca Pierdomenico, MD, Antonio Almeida, MD, PhD

Blood (2011) 118 (21): 4285.

https://doi.org/10.1182/blood.V118.21.4285.4285

Published: 2011

Journal Articles

Efficacy, Tolerability and Cost Benefit of a 5-Day Azacitidine Regimen

Francesca Pierdomenico, MD, Antonio Almeida, MD, PhD

Blood (2011) 118 (21): 5034.

https://doi.org/10.1182/blood.V118.21.5034.5034

Published: 2011

Journal Articles

Identification of Molecular Mechanisms by Which Histone Deacetylase Inhibitors Modulate Gene Expression In Hematopoietic Cells

Gabriela Silva, PhD, Maria Silva, MD, PhD, Antonio Parreira, MD, PhD, Antonio Almeida, MD, PhD

Blood (2010) 116 (21): 4448.

https://doi.org/10.1182/blood.V116.21.4448.4448

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Vorinostat Impairs Cellular Viability, Differentiation, Redox Homeostasis and Gene Expression in BCR-ABL-Negative Myeloproliferative Neoplasms

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Epigenetic Alterations In Fanconi Anemia: Role In Disease Progression and Therapeutic Potential

Azacitidine for the Treatment of Acute Erythroleukemia: Three Case Reports

Efficacy, Tolerability and Cost Benefit of a 5-Day Azacitidine Regimen

Identification of Molecular Mechanisms by Which Histone Deacetylase Inhibitors Modulate Gene Expression In Hematopoietic Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only